Ocrevus (ocrelizumab) - Maphunziro Othandiza

Ocrevus (ocrelizumab) ndi mankhwala achilengedwe omwe amagwiritsidwa ntchito pochiza multiple sclerosis (MS) ndi nyamakazi ya nyamakazi (RA). Mankhwalawa adavomerezedwa ndi FDA mu 2017 pochiza MS komanso mu 2021 pochiza RA.

Zochita za Ocrevus zimachokera ku kutsekereza mapuloteni a CD20, omwe amapezeka pamwamba pa maselo ena a chitetezo cha mthupi, kuphatikizapo maselo omwe amagwira ntchito yofunika kwambiri pa chitukuko cha MS ndi RA. Kuletsa mapuloteni a CD20 kungachepetse ntchito ya chitetezo cha mthupi komanso kuchepetsa njira zotupa zomwe zimayambitsa kuwonongeka kwa minofu.

Maphunziro a mphamvu ya Ocrevus pochiza MS ndi RA akhala akuchitika kwa zaka zingapo. Mmodzi mwa maphunziro oyamba, omwe adasindikizidwa mu The Lancet mu 2017, adatchedwa "Kuchita bwino ndi chitetezo cha Ocrevus mu primary progressive multiple sclerosis." Kafukufukuyu adachitidwa pa odwala opitilira 700 omwe adalandira Ocrevus kapena placebo kwa milungu 96. Zotsatira zake zidawonetsa kuti Ocrevus adachepetsa kwambiri kupita patsogolo kwa MS poyerekeza ndi placebo.

Kafukufuku wina wofalitsidwa mu The New England Journal of Medicine mu 2017 adafufuza mphamvu ya Ocrevus mu relapsing-remitting multiple sclerosis (RRMS). Kafukufukuyu adachitidwa pa odwala oposa 1300 omwe adalandira Ocrevus kapena mankhwala ena ochizira RRMS. Zotsatira zake zidawonetsa kuti Ocrevus adachepetsa kwambiri kuchuluka kwa odwala omwe abwereranso kuchira poyerekeza ndi mankhwala ena.

Maphunziro okhudza mphamvu ya Ocrevus ku RA yachitikanso. M'modzi wa iwo, wofalitsidwa mu The Lancet mu 2019, adawunika mphamvu ya Ocrevus mu seropositive RA, yomwe ndi imodzi mwazovuta kwambiri.